Species

VAXXITEK® 
HVT+IBD+ND

Designed For You

 

 

Details

 

VAXXITEK® HVT+IBD+ND represents a breakthrough in hatchery vaccination. A 3-in-1 vaccine, it provides a strong immune foundation and optimized protection against Marek’s disease (MD), infectious bursal disease (IBD), and Newcastle disease (ND).1

 

  • All the benefits of VAXXITEK® HVT+IBD, now designed with ND protection

  • Simplified vaccination protocol that protects against 3 of the most infectious and commercially disruptive flock diseases

  • Herpesvirus of turkeys (HVT)-based vector vaccine; worldwide renowned technology

  • Safe and easy to use

 

Key Advantages

  • Only one hatchery administration at day old or in ovo

  • One single vaccination to protect against MD, IBD, and ND1

  • Early-onset and long duration of immunity, for protection throughout susceptible periods1

  • Demonstrated safety by monitoring of body weight gain, for improved production performance1

  • Genotype VII ND insert, for universal protection

  • Efficient protection against a variety of IBD virus (IBDV) strains2-4

  • Rapid and long-lasting protection against velogenic ND virus5-7

  • Onset of immunity against MD shown from 5 days of age8,9

 

VAXXITEK HVT+BD+ND

Features & Benefits

  • 3-in-1 vaccine: MD, IBD, and ND protection

  • Same technology platform as VAXXITEK® HVT+IBD that ensures proper gene expression

  • Strong immune foundation enables productivity, reduces antibiotic use, and supports return on investment

  • Reduced labor, time, and cost enable increased profitability

  • Improved animal welfare through fewer vaccine applications

  • Only one hatchery administration at 1 day of age or in ovo

Dosage & Administration

  • Packaged in 5 x 4000 dose ampules in frozen presentation
Resources

E-Detailer

Vaxxitek HVT-IBD-ND Sales Aid

 

 

 

 

US-POU-0020-2019

 

View E-Detailer ▸

Safety

  • Do not mix with other products, except as specified on the label

  • In case of human exposure, contact a physician

  • Administer only as recommended

  • Use entire contents when first opened

  • Do not vaccinate within 21 days before slaughter

  • Contains penicillin and streptomycin sulfate, which are added as bacteriostatic agents

  • Contains amphotericin B as a fungistatic agent

  • Inactivate unused contents before disposal

  • Safety comparable to existing HVT vector vaccines10

  • Proven to remain safe and stable; will not revert to virulence11

 

Safety Data Sheet

VAXXITEK HVT+IBD+ND
References

1Data on file at Boehringer Ingelheim.

2Data on file at Boehringer Ingelheim. 2016, Report number 16-083.

3Data on file at Boehringer Ingelheim. 2017, Report number 16-194.

4Data on file at Boehringer Ingelheim. R&D, 2018, Report number 16-0325.

5Data on file at Boehringer Ingelheim. 2017, Report number 16–191.

6Data on file at Boehringer Ingelheim. 2018, Report number 16–190.

7Data on file at Boehringer Ingelheim. 2017, Report number 16–0499.

8Data on file at Boehringer Ingelheim. 2018, Report number 16-189.

9Data on file at Boehringer Ingelheim. 2018, Report number 17-111.

10Data on file at Boehringer Ingelheim. 2017, Report number 16-187.

11Data on file at Boehringer Ingelheim. R&D, 2017, Report number 17.0107.R.

Trademarks

VAXXITEK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-POU-0058-2022

CAUTION

NEWCASTLE DISEASE CAN CAUSE INFLAMMATION OF THE EYELIDS OF HUMANS. EYE PROTECTION MUST BE WORN WHEN REHYDRATING AND ADMINISTERING THIS VACCINE. AVOID CONTAMINATING HANDS AND CLOTHING WITH THE VACCINE. HAND WASHING IS RECOMMENDED AFTER EXPOSURE TO THE PRODUCT.